Faculty profile

Philip Hieter

ResearcherMichael Smith LaboratoriesUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses may be missing. Find their university profile.

Philip Hieter

Researcher

Michael Smith Laboratories

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
7 publications in the last five years, latest in 2025.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 6 research grants (6 CIHR), most recently in 2022.
Supervised 5 trainees who won CIHR awards, most recently in 2012.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Bioinformatics Gene Functional Analysis Genetics Knowledge Translation Model Organisms Therapeutic Strategies Rare Diseases Dna Repair

Latest papers

Synthetic cytotoxicity profiling of cohesin mutants highlights recombination-based dependencies.
DNA repair · 2025 · senior author
Global partnerships in rare disease research.
Disease models & mechanisms · 2025
Deep structure-function analysis of the endonuclease Mus81 with dominant mutational scanning.
Proceedings of the National Academy of Sciences of the United States of America · 2025 · senior author

All 51 publications

Latest funding

Canadian "Rare Diseases: Models and Mechanisms" (RDMM) Network
CIHR · 2022 · Nominated PI
$2,500,000
Canadian "Rare Diseases: Models and Mechanisms" (RDMM) Network
CIHR · 2018 · Nominated PI
$1,119,500
Targeting the dynamics and genomics of clonal evolution in cancer patients
CIHR · 2015 · Co-investigator
$2,833,460

All 17 grants and awards

51 publications.

Synthetic cytotoxicity profiling of cohesin mutants highlights recombination-based dependencies.

Marodin RH, Cozma E, Reytan-Miron S, O'Neil NJ, Stirling PC, Hieter P

DNA repair2025Senior author

DOI: 10.1016/j.dnarep.2025.103871 PMID: 40684628

Global partnerships in rare disease research.

Rogic S, Poirier-Morency G, Hieter P, Pavlidis P

Disease models & mechanisms2025

DOI: 10.1242/dmm.052401 PMID: 40719025

Deep structure-function analysis of the endonuclease Mus81 with dominant mutational scanning.

Oppedisano A, Bailey ML, Kumar A, O'Neil NJ, Stirling PC, Hieter P

Proceedings of the National Academy of Sciences of the United States of America2025Senior author

DOI: 10.1073/pnas.2506043122 PMID: 40531874

Mapping of DDX11 genetic interactions defines sister chromatid cohesion as the major dependency.

Amitzi L, Cozma E, Tong AHY, Chan K, Ross C, O'Neil N, Moffat J, Stirling P, Hieter P

G3 (Bethesda, Md.)2024Senior author

DOI: 10.1093/g3journal/jkae052 PMID: 38478595

Highlighting rare disease research with a GENETICS and G3 series on genetic models of rare diseases.

Hieter P, Andrews B, Fowler D, Bellen H

G3 (Bethesda, Md.)2023First author

DOI: 10.1093/g3journal/jkad144 PMID: 37556359

Highlighting rare disease research with a GENETICS and G3 series on genetic models of rare diseases.

Hieter P, Andrews B, Fowler D, Bellen H

Genetics2023First author

DOI: 10.1093/genetics/iyad121 PMID: 37556311

ModelMatcher: A scientist-centric online platform to facilitate collaborations between stakeholders of rare and undiagnosed disease research.

Harnish JM, Li L, Rogic S, Poirier-Morency G, Kim SY, Undiagnosed Diseases Network, Boycott KM, Wangler MF, Bellen HJ, Hieter P, Pavlidis P, Liu Z, Yamamoto S

Human mutation2022

DOI: 10.1002/humu.24364 PMID: 35224820

Paralogous synthetic lethality underlies genetic dependencies of the cancer-mutated gene STAG2.

Bailey ML, Tieu D, Habsid A, Tong AHY, Chan K, Moffat J, Hieter P

Life science alliance2021Senior author

DOI: 10.26508/lsa.202101083 PMID: 34462321

A nuclear proteome localization screen reveals the exquisite specificity of Gpn2 in RNA polymerase biogenesis.

Minaker SW, Kofoed MC, Hieter P, Stirling PC

Cell cycle (Georgetown, Tex.)2021

DOI: 10.1080/15384101.2021.1943879 PMID: 34180355

Modeling DNA trapping of anticancer therapeutic targets using missense mutations identifies dominant synthetic lethal interactions.

Hamza A, Amitzi L, Ma L, Driessen MRM, O'Neil NJ, Hieter P

Proceedings of the National Academy of Sciences of the United States of America2021Senior author

DOI: 10.1073/pnas.2100240118 PMID: 33782138

Canadian "Rare Diseases: Models and Mechanisms" (RDMM) Network

Nominated PICIHR2022Research Network: Rare Diseases

Principal investigators: Hieter, Philip A; Boycott, Kym M; Campeau, Philippe M

Keywords: Bioinformatics; Gene Functional Analysis; Genetics; Knowledge Translation; Model Organisms; Rare Diseases; Therapeutic Strategies

$2,500,000

Canadian "Rare Diseases: Models and Mechanisms" (RDMM) Network

Nominated PICIHR2018Research Network: Rare Diseases

Principal investigators: Hieter, Philip A; Boycott, Kym M; Campeau, Philippe M

Keywords: Bioinformatics; Gene Functional Analysis; Genetics; Knowledge Translation; Model Organisms; Rare Diseases; Therapeutic Strategies

$1,119,500

Targeting the dynamics and genomics of clonal evolution in cancer patients

Co-investigatorCIHR2015Foundation Grant

Principal investigators: Aparicio, Samuel J

Keywords: Breast Cancer; Cancer; Clonal Evolution; Clonal Genomes; Genomics; Oncology; Patient-Derived Xenografts; Single Cell; Therapeutics; Translational Medicine

$2,833,460

Chromosome instability and synthetic lethality in yeast and cancer

Nominated PICIHR2015Foundation Grant

Principal investigators: Hieter, Philip A

Keywords: C. Elegans Genetics; Cancer Therapeutics; Chromosome Biology; Chromosome Instability Genes; Dna Repair; Genome Stability; Mechanisms Of Aneuploidy; Model Organisms And Human Disease; Synthetic Lethality; Yeast Genetics

$2,526,307

The clonal dynamics of ovarian cancers: phylogenetic models of chemosensitivity and resistance

Co-investigatorCIHR2014Foundation Grant

Principal investigators: Shah, Sohrab P

Keywords: Clonal Dynamics; Computational Biology; Dna Repair; Genomic Instability; Genomic Signatures; Homologous Recombination; Next-Generation Sequencing; Ovarian Cancer; Response Prediction; Tumour Evolution

$910,631

Canadian "Rare Diseases: Models & Mechanisms" Network (RDMM) Réseau Canadien "Maladies Rares: Modèles et Mécanismes" (MRMM)

Nominated PICIHR2014Research Network: Rare Diseases

Principal investigators: Hieter, Philip A; Boycott, Kym M; Rossant, Janet

Keywords: Bioinformatics; Collaborative Studies; Gene Functional Analysis; Genetics; Knowledge Translation; Model Organisms; Rare Disease Genes; Therapeutic Strategies

$2,100,000

Large scale analysis of synthetic cytotoxic interactions with DNA damaging therapeutic agents

Nominated PICIHR2013Operating Grant

Principal investigators: Hieter, Philip A

Keywords: Chemi-Genetic Network; Dna Damaging Agent; Dna Repair; Genetic Interaction Maps; High Throughput Analysis; Large-Scale Screening; Robotics; Saccharomyces Cerevisiae; Synthetic Cytotoxicity; Synthetic Genetic Array

$666,120

Dosage CIN: A comprehensive analysis of gene dosage effects on genome stability

SupervisorCIHR2012Banting Postdoctoral Fellowship Program

Principal investigators: Kaluarachchi Duffy, Supipi

Keywords: Chromosome Instability; Gene Amplification; Gene Over-Expression; Genome Instability

$140,000

Human complementation of yeast mutations to identify candidate cancer therapeutic targets

SupervisorCIHR2012Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Hamza, Akil

Keywords: Cancer Predisposing Genes; Chromosome Instability (Cin) Genes; Complementation; Saccharomyces Cerevisiae; Synthetic Genetic Analysis; Synthetic Lethality; Tumor-Specific Mutations

$105,000

Identification of synthetic cytotoxic interactions to improve the efficacy of DNA damaging therapeutic agents

SupervisorCIHR2011Doctoral Research Award-PA: Ionizing Radiation - Medical Uses and Health Effects

Principal investigators: Moshgabadi, Noushin

Keywords: Cancer; Cancer Somatic Mutations; Cancer Therapy; Dna Damaging Therapeutic Agents; Dna Repair Enzymes; Ionization Radiation; Mammalian Cell Culture; Saccharomyces Cerevisiae; Sirna; Synthetic Cytotoxic Interactions

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Philip Hieter

Research

Latest papers

Latest funding

Synthetic cytotoxicity profiling of cohesin mutants highlights recombination-based dependencies.

Global partnerships in rare disease research.

Deep structure-function analysis of the endonuclease Mus81 with dominant mutational scanning.

Mapping of DDX11 genetic interactions defines sister chromatid cohesion as the major dependency.

Highlighting rare disease research with a GENETICS and G3 series on genetic models of rare diseases.

Highlighting rare disease research with a GENETICS and G3 series on genetic models of rare diseases.

ModelMatcher: A scientist-centric online platform to facilitate collaborations between stakeholders of rare and undiagnosed disease research.

Paralogous synthetic lethality underlies genetic dependencies of the cancer-mutated gene STAG2.

A nuclear proteome localization screen reveals the exquisite specificity of Gpn2 in RNA polymerase biogenesis.

Modeling DNA trapping of anticancer therapeutic targets using missense mutations identifies dominant synthetic lethal interactions.

Canadian "Rare Diseases: Models and Mechanisms" (RDMM) Network

Canadian "Rare Diseases: Models and Mechanisms" (RDMM) Network

Targeting the dynamics and genomics of clonal evolution in cancer patients

Chromosome instability and synthetic lethality in yeast and cancer

The clonal dynamics of ovarian cancers: phylogenetic models of chemosensitivity and resistance

Canadian "Rare Diseases: Models & Mechanisms" Network (RDMM) Réseau Canadien "Maladies Rares: Modèles et Mécanismes" (MRMM)

Large scale analysis of synthetic cytotoxic interactions with DNA damaging therapeutic agents

Dosage CIN: A comprehensive analysis of gene dosage effects on genome stability

Human complementation of yeast mutations to identify candidate cancer therapeutic targets

Identification of synthetic cytotoxic interactions to improve the efficacy of DNA damaging therapeutic agents

Frequent collaborators

Jason Moffat

Brenda Andrews

Paul Pavlidis

Corey Nislow

Jean-Yves Masson

Leann Howe

Thierry Lacaze-Masmonteil

Xiao-Yan Wen

Peter Stirling

Taila Hartley

Thierry Lacaze-Masmonteil

Catharine Rankin

Anne Junker

David Dyment

Michael Brudno